Gustavo Girotto

ORCID: 0000-0002-4098-1320

3

h-index

3

Publications

8,117

Citations

Publications

3 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

2019 The Lancet 2928 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Frequent Co-Authors

Tony Mok

Chinese University of Hong Kong

Yi‐Long Wu

Guangdong Provincial People's Hospital

Iveta Kudaba

Riga East University Hospital

Dariusz M. Kowalski

Université Toulouse III - Paul Sabatier

Byoung Chul Cho

Yonsei University

H.Z. Turna

Istanbul University

Researcher Info

h-index: 3
Publications: 3
Citations: 8,117

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-4098-1320

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.